If that was true then how did Epclusa or Mavyret make it to the market?
July 11, 2026 at 9:03 PM
If that was true then how did Epclusa or Mavyret make it to the market?
I assure you that when they find a cure for a disease, they have absolutely no problem whatsoever making money from it, because insurance companies will generally pay as long as it's lesser than the lifetime cost of treatment. See, eg, Mavyret which is something like a 99% effective Hep C cure.
May 20, 2024 at 1:04 PM
I assure you that when they find a cure for a disease, they have absolutely no problem whatsoever making money from it, because insurance companies will generally pay as long as it's lesser than the lifetime cost of treatment. See, eg, Mavyret which is something like a 99% effective Hep C cure.
Mavyret I received for free Hep C healed for 2 years. 🎉🥳
August 3, 2025 at 12:41 AM
Mavyret I received for free Hep C healed for 2 years. 🎉🥳
#OTILT Mavyret (glecaprevir/pibrentasvir) is a substrate of P-gp and hepatic transporter OATP1B1/3. Due to this pharmacokinetic profile, co-administration of Mavyret with atorvastatin should be avoided. However, concomitant use of rosuvastatin is safe as long as the dose does not exceed 10mg.
November 4, 2025 at 8:01 PM
#OTILT Mavyret (glecaprevir/pibrentasvir) is a substrate of P-gp and hepatic transporter OATP1B1/3. Due to this pharmacokinetic profile, co-administration of Mavyret with atorvastatin should be avoided. However, concomitant use of rosuvastatin is safe as long as the dose does not exceed 10mg.
FDA Approves Mavyret for Acute Hepatitis C - POZ
www.poz.com/article/fda-...
> Treating hepatitis C early can alleviate symptoms and prevent transmission of the virus.
www.poz.com/article/fda-...
> Treating hepatitis C early can alleviate symptoms and prevent transmission of the virus.
FDA Approves Mavyret for Acute Hepatitis C
Treating hepatitis C early can alleviate symptoms and prevent transmission of the virus.
www.poz.com
June 13, 2025 at 1:51 PM
FDA Approves Mavyret for Acute Hepatitis C - POZ
www.poz.com/article/fda-...
> Treating hepatitis C early can alleviate symptoms and prevent transmission of the virus.
www.poz.com/article/fda-...
> Treating hepatitis C early can alleviate symptoms and prevent transmission of the virus.
US FDA Approves Expanded Indication For Abbvie's Mavyret® As First And Only Treatment For People With Acute Hepatitis C Virus
June 11, 2025 at 4:33 PM
US FDA Approves Expanded Indication For Abbvie's Mavyret® As First And Only Treatment For People With Acute Hepatitis C Virus
i think there's only one dosage strength they just adjust the duration of the treatment
mavyret
mavyret
January 11, 2024 at 8:25 PM
i think there's only one dosage strength they just adjust the duration of the treatment
mavyret
mavyret
We're almost 3 full months into trying to get him treatment, he's exploring going to India where the drug is 1/3 the cost that it is in the US, and thankfully on the 4th appeal Anthem finally agreed to the treatment. He was prescribed an alternate drug called Mavyret.
December 6, 2024 at 9:30 PM
We're almost 3 full months into trying to get him treatment, he's exploring going to India where the drug is 1/3 the cost that it is in the US, and thankfully on the 4th appeal Anthem finally agreed to the treatment. He was prescribed an alternate drug called Mavyret.
#OTILT Mavyret can increase the serum concentrations of Truvada as it is a mild Pg-p inhibitor and closer monitoring of Tenofavir side effects is recommended with coadministration @yoon-jun.bsky.social @sophiaylee.bsky.social @bwdionne.bsky.social @jeffpears0n.bsky.social
November 4, 2025 at 10:06 PM
#OTILT Mavyret can increase the serum concentrations of Truvada as it is a mild Pg-p inhibitor and closer monitoring of Tenofavir side effects is recommended with coadministration @yoon-jun.bsky.social @sophiaylee.bsky.social @bwdionne.bsky.social @jeffpears0n.bsky.social
Notes to self: Hep C treatment
Glecaprevir-Pibrentasvir vs Sofosbuvir-Velpatasvir
Glecaprevir/Pibrentasvir (GLE/PIB) Mavyret
-effective across all genotypes
- 8 weeks of tx: 3 tablets daily
-cons: contraindicated in patients with decompensated cirrhosis (Child-Pugh B or C)
Glecaprevir-Pibrentasvir vs Sofosbuvir-Velpatasvir
Glecaprevir/Pibrentasvir (GLE/PIB) Mavyret
-effective across all genotypes
- 8 weeks of tx: 3 tablets daily
-cons: contraindicated in patients with decompensated cirrhosis (Child-Pugh B or C)
November 28, 2024 at 4:06 AM
Notes to self: Hep C treatment
Glecaprevir-Pibrentasvir vs Sofosbuvir-Velpatasvir
Glecaprevir/Pibrentasvir (GLE/PIB) Mavyret
-effective across all genotypes
- 8 weeks of tx: 3 tablets daily
-cons: contraindicated in patients with decompensated cirrhosis (Child-Pugh B or C)
Glecaprevir-Pibrentasvir vs Sofosbuvir-Velpatasvir
Glecaprevir/Pibrentasvir (GLE/PIB) Mavyret
-effective across all genotypes
- 8 weeks of tx: 3 tablets daily
-cons: contraindicated in patients with decompensated cirrhosis (Child-Pugh B or C)
The #FDA has granted expanded approval to AbbVie's glecaprevir/pibrentasvir (Mavyret) to include patients aged 3 years and older with acute or chronic #hepatitis C virus (HCV). #Medsky #Pedsky
Full story and study data that led to approval: www.contemporarypediatrics.com/view/fda-exp...
Full story and study data that led to approval: www.contemporarypediatrics.com/view/fda-exp...
June 12, 2025 at 7:26 PM
The #FDA has granted expanded approval to AbbVie's glecaprevir/pibrentasvir (Mavyret) to include patients aged 3 years and older with acute or chronic #hepatitis C virus (HCV). #Medsky #Pedsky
Full story and study data that led to approval: www.contemporarypediatrics.com/view/fda-exp...
Full story and study data that led to approval: www.contemporarypediatrics.com/view/fda-exp...
#OTILT First-line hepC tx (Mavyret and Epclusa) are pan-genotypic. If a pt develops hepC again, genotyping is useful since it determines whether infection is a recurrence or a new infection - which guides whether the pt should receive standard first-line therapy again or move to a salvage regimen.
September 19, 2025 at 7:43 PM
#OTILT First-line hepC tx (Mavyret and Epclusa) are pan-genotypic. If a pt develops hepC again, genotyping is useful since it determines whether infection is a recurrence or a new infection - which guides whether the pt should receive standard first-line therapy again or move to a salvage regimen.
Mavyret & Sovaldi for Hep C cost around $12,000. Usually covered by medicaid & health insurers. It’s an expensive drug to take patients down to undetectable levels. The case count is decreasing. Not sure on the correlation between active cases and vaccine schedules with Hep B. Good idea for debate.
December 24, 2024 at 12:38 AM
Mavyret & Sovaldi for Hep C cost around $12,000. Usually covered by medicaid & health insurers. It’s an expensive drug to take patients down to undetectable levels. The case count is decreasing. Not sure on the correlation between active cases and vaccine schedules with Hep B. Good idea for debate.
Starting the week with our weekly roundup of key IP developments and posts on Mavyret patent abandonment, calls for comments on new patent and trademark manuals, and the DHC’s decision in Intra Cellular Therapies v. Controller. (1/2)
August 24, 2026 at 7:17 AM
Starting the week with our weekly roundup of key IP developments and posts on Mavyret patent abandonment, calls for comments on new patent and trademark manuals, and the DHC’s decision in Intra Cellular Therapies v. Controller. (1/2)
Does one patent refusal directly equate to entry for generics? A patent application on AbbVie's Mavyret, most effective for curing patients of Hepatitis C Virus was refused by the IPO in May 2026, but a closer look at the patent landscape reveals why one patent abandonment (1/2)
August 24, 2026 at 4:43 AM
Does one patent refusal directly equate to entry for generics? A patent application on AbbVie's Mavyret, most effective for curing patients of Hepatitis C Virus was refused by the IPO in May 2026, but a closer look at the patent landscape reveals why one patent abandonment (1/2)
This and a lot more in this week’s SpicyIP Weekly Review. Anything we are missing out on? Drop a comment and let us know below. (2/2)
spicyip.com/2026/08/spic...
spicyip.com/2026/08/spic...
SpicyIP Weekly Review (August 17-August 23)
Starting the week with our weekly roundup of key IP developments and posts on Mavyret patent abandonment, calls for comments on new patent and trademark manuals, and the DHC’s decision in Intra Cel…
spicyip.com
August 24, 2026 at 7:17 AM
This and a lot more in this week’s SpicyIP Weekly Review. Anything we are missing out on? Drop a comment and let us know below. (2/2)
spicyip.com/2026/08/spic...
spicyip.com/2026/08/spic...
may not be enough for Indian HCV patients to access the drug. In this post, Ambika Aggarwal discusses concerns, strategic choices and the larger story of AbbVie's Hepatitis C patents in India.
spicyip.com/2026/08/mavy... (2/2)
spicyip.com/2026/08/mavy... (2/2)
Mavyret Patent Abandonment Does Not Open the Field for Hepatitis C Generics
July 28, 2026 marked eight years of the National Viral Hepatitis Control Program (NVHCP). Launched under the National Health Mission, the program aims to eliminate Hepatitis C from India by 2030 th…
spicyip.com
August 24, 2026 at 4:43 AM
may not be enough for Indian HCV patients to access the drug. In this post, Ambika Aggarwal discusses concerns, strategic choices and the larger story of AbbVie's Hepatitis C patents in India.
spicyip.com/2026/08/mavy... (2/2)
spicyip.com/2026/08/mavy... (2/2)
I just got a prescription for Mavyret. Wholesale cost to me = $12,843 for a 1 month supply.
That was not a typo.
That was not a typo.
December 13, 2024 at 6:25 PM
I just got a prescription for Mavyret. Wholesale cost to me = $12,843 for a 1 month supply.
That was not a typo.
That was not a typo.
艾伯维（AbbVie）迎来重大发展：FDA批准Mavyret治疗急性丙型肝炎病毒感染标签扩展
https://qian.cx/posts/100768B3-48C1-4F10-9919-6F6410E9DD67
https://qian.cx/posts/100768B3-48C1-4F10-9919-6F6410E9DD67
September 7, 2025 at 9:45 AM
艾伯维（AbbVie）迎来重大发展：FDA批准Mavyret治疗急性丙型肝炎病毒感染标签扩展
https://qian.cx/posts/100768B3-48C1-4F10-9919-6F6410E9DD67
https://qian.cx/posts/100768B3-48C1-4F10-9919-6F6410E9DD67
艾伯维（AbbVie）获FDA批准扩展Mavyret适应症，为儿童和成人丙型肝炎治疗带来新突破
https://qian.cx/posts/721D7D93-2C95-40D9-83B2-1DF652F9F74D
https://qian.cx/posts/721D7D93-2C95-40D9-83B2-1DF652F9F74D
September 4, 2025 at 10:37 AM
艾伯维（AbbVie）获FDA批准扩展Mavyret适应症，为儿童和成人丙型肝炎治疗带来新突破
https://qian.cx/posts/721D7D93-2C95-40D9-83B2-1DF652F9F74D
https://qian.cx/posts/721D7D93-2C95-40D9-83B2-1DF652F9F74D